Phase 1b/2a Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKACE) In Cystic Fibrosis Patients With Chronic Infections Due To Pseudomonas Aeruginosa.
Phase of Trial: Phase I/II
Latest Information Update: 03 Oct 2017
At a glance
- Drugs Amikacin (Primary)
- Indications Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections
- Focus Adverse reactions
- Sponsors Insmed
- 04 May 2012 Actual end date (1 Feb 2010) added as reported by ClinicalTrials.gov.
- 04 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Jun 2011 Results presented at the 34th European Cystic Fibrosis Conference, according to a Insmed media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History